Dr. Lawrence Mayer on CPX-351 for Acute Myeloid Leukemia

Lawrence Mayer, PhD,
Published: Friday, Jan 23, 2015

Lawrence Mayer, PhD, president, founder and chief scientific officer of Celator Pharmaceuticals, explains the technology behind CPX-351, a  liposomal formulation of cytarabine and daunorubicin. CPX-351 was recently granted Fast Track Designation by the FDA for the treatment of elderly patients with relapsed acute myeloid leukemia (AML).

CPX-351 utilizes CombiPlex, a drug ratio technology platform, which identifies the optimal ratio of a drug that will deliver a synergistic benefit to tumor cells, and locks in and maintains that desired ratio.  

CPX-351 provides extended circulation lifetime and accumulation in the bone marrow, where the tumor cells grown and reside in AML patients. The drug accumulates less in normal tissue when compared to conventional treatments, reducing toxicity and improving efficacy, says Mayer. 

Lawrence Mayer, PhD, president, founder and chief scientific officer of Celator Pharmaceuticals, explains the technology behind CPX-351, a  liposomal formulation of cytarabine and daunorubicin. CPX-351 was recently granted Fast Track Designation by the FDA for the treatment of elderly patients with relapsed acute myeloid leukemia (AML).

CPX-351 utilizes CombiPlex, a drug ratio technology platform, which identifies the optimal ratio of a drug that will deliver a synergistic benefit to tumor cells, and locks in and maintains that desired ratio.  

CPX-351 provides extended circulation lifetime and accumulation in the bone marrow, where the tumor cells grown and reside in AML patients. The drug accumulates less in normal tissue when compared to conventional treatments, reducing toxicity and improving efficacy, says Mayer. 


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x